Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial-Reference-Cited by-同舟云学术

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Published:2014-05-13 Issue:12 Volume:110 Page:2821-2828
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Escudier B,Michaelson M D,Motzer R J,Hutson T E,Clark J I,Lim H Y,Porfiri E,Zalewski P,Kannourakis G,Staehler M,Tarazi J,Rosbrook B,Cisar L,Hariharan S,Kim S,Rini B I

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014244.pdf

Reference21 articles.

1. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY (2013) The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 8: 203–209.

2. Basappa NS, Elson P, Golshayan AR, Wood L, Garcia JA, Dreicer R, Rini BI (2011) The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer 117: 1183–1189.

3. Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, Rosbrook B, Kim S, Motzer R (2013) Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 108: 1571–1578.

4. Cohen RB, Oudard S (2012) Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 30: 2066–2079.

5. Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V (2012) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (suppl 7): vii65–vii71.

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Metastatic Renal Cell Carcinoma;A Guide to Management of Urological Cancers;2023

2. Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma;Journal of Kidney Cancer and VHL;2022-09-29

3. Avelumab plus axitinib combination in treating metastatic renal cell carcinoma;Onkologie;2022-09-29

4. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma;Radiation Oncology;2021-11-02

5. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma;Japanese Journal of Clinical Oncology;2021-09-08